ChIP-Seq Profiling of ASCL1 Binding
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : University of Cambridge, Wellcome/MRC Cambridge Stem Cell Institute, Mohammed Bin Rashid University of Medicine and Health Sciences, Cancer Research UK
Protocol cited in 2 other protocols
Variable analysis
- Genotype (WT vs. S-A SH-SY5Y tetracycline-inducible stable cell lines)
- Doxycycline treatment (1 μg/ml for 24 hours)
- ASCL1 binding detected by ChIP-seq
- Cell line (SH-SY5Y)
- Antibodies used (anti-ASCL1 and anti-IgG)
- Positive control: anti-ASCL1 antibody
- Negative control: anti-IgG antibody
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!